Antibacterial activity of carbapenems against clinical isolates of respiratory bacterial pathogens in the northeastern region of Japan in 2007

Gomi, Katsushige; Fujimura, Shigeru; Fuse, Katsuhiro; Takane, Hidenari; Nakano, Yoshiaki; Kariya, Yasuko; Kikuchi, Toshiaki; Kurokawa, Iku; Tokue, Yutaka; Watanabe, Akira

doi:10.1007/s10156-010-0112-2

Cited by 6 publications

(1 citation statement)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Like other carbapenems, biapenem is not affected by the presence of ESBLs but is labile to hydrolysis by both serine and metallo-carbapenemases (164). Although carbapenem resistance is increasing, Ͼ75% of recent Japanese pseudomonal isolates were susceptible to biapenem and meropenem (165). Pharmacologically, biapenem is notable for its low proconvulsive activity compared to that of imipenem (166).…”

Section: ␤-Lactamase Inhibitor Combinationsmentioning

confidence: 99%

Investigational Antimicrobial Agents of 2013

Pucci

Bush

2013

Clin Microbiol Rev

View full text Add to dashboard Cite

SUMMARY New antimicrobial agents are always needed to counteract the resistant pathogens that continue to be selected by current therapeutic regimens. This review provides a survey of known antimicrobial agents that were currently in clinical development in the fall of 2012 and spring of 2013. Data were collected from published literature primarily from 2010 to 2012, meeting abstracts (2011 to 2012), government websites, and company websites when appropriate. Compared to what was reported in previous surveys, a surprising number of new agents are currently in company pipelines, particularly in phase 3 clinical development. Familiar antibacterial classes of the quinolones, tetracyclines, oxazolidinones, glycopeptides, and cephalosporins are represented by entities with enhanced antimicrobial or pharmacological properties. More importantly, compounds of novel chemical structures targeting bacterial pathways not previously exploited are under development. Some of the most promising compounds include novel β-lactamase inhibitor combinations that target many multidrug-resistant Gram-negative bacteria, a critical medical need. Although new antimicrobial agents will continue to be needed to address increasing antibiotic resistance, there are novel agents in development to tackle at least some of the more worrisome pathogens in the current nosocomial setting.

show abstract

Section: ␤-Lactamase Inhibitor Combinationsmentioning

confidence: 99%